APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihypertensive Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antihypertensive Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchAntihypertensive Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihypertensive Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Antihypertensive Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihypertensive Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihypertensive Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antihypertensive Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antihypertensive Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antihypertensive Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihypertensive Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antihypertensive Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antihypertensive Drugs include Takeda, Sanofi, Johnson & Johnson, Novartis, Merck, Pfizer, United Therapeutics, Ranbaxy Laboratories and Lupin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antihypertensive Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antihypertensive Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antihypertensive Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antihypertensive Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Antihypertensive Drugs Segment by Company

Takeda

Sanofi

Johnson & Johnson

Novartis

Merck

Pfizer

United Therapeutics

Ranbaxy Laboratories

Lupin

Daiichi Sankyo

Astra Zeneca

Actelion

Antihypertensive Drugs Segment by Type

Calcium Antagonist Medicine

Sympathetic Suppressant

Diuretic Antihypertensive

Renin-angiotensin System Inhibitor

vasodilator

Antihypertensive Drugs Segment by Application

Pregnant Woman

General Patient

The Old

Antihypertensive Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihypertensive Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihypertensive Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihypertensive Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antihypertensive Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antihypertensive Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antihypertensive Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antihypertensive Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antihypertensive Drugs Industry Trends Table 2. Antihypertensive Drugs Industry Drivers Table 3. Antihypertensive Drugs Industry Opportunities and Challenges Table 4. Antihypertensive Drugs Industry Restraints Table 5. Global Antihypertensive Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antihypertensive Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antihypertensive Drugs Sales by Manufacturers (M Pcs) & (2021-2026) Table 8. Global Antihypertensive Drugs Sales Market Share by Manufacturers Table 9. Global Antihypertensive Drugs Average Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 10. Global Antihypertensive Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antihypertensive Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antihypertensive Drugs Manufacturers, Product Type & Application Table 13. Global Antihypertensive Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antihypertensive Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Calcium Antagonist Medicine Table 17. Major Manufacturers of Sympathetic Suppressant Table 18. Major Manufacturers of Diuretic Antihypertensive Table 19. Major Manufacturers of Renin-angiotensin System Inhibitor Table 20. Major Manufacturers of vasodilator Table 21. Global Antihypertensive Drugs Sales by Type 2021 VS 2025 VS 2032 (M Pcs) Table 22. Global Antihypertensive Drugs Sales by Type (2021-2026) & (M Pcs) Table 23. Global Antihypertensive Drugs Sales by Type (2027-2032) & (M Pcs) Table 24. Global Antihypertensive Drugs Sales Market Share by Type (2021-2026) Table 25. Global Antihypertensive Drugs Sales Market Share by Type (2027-2032) Table 26. Global Antihypertensive Drugs Revenue by Type 2021 VS 2025 VS 2032 (M Pcs) Table 27. Global Antihypertensive Drugs Revenue by Type (2021-2026) & (M Pcs) Table 28. Global Antihypertensive Drugs Revenue by Type (2027-2032) & (M Pcs) Table 29. Global Antihypertensive Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Antihypertensive Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Pregnant Woman Table 32. Major Manufacturers of General Patient Table 33. Major Manufacturers of The Old Table 34. Global Antihypertensive Drugs Sales by Application 2021 VS 2025 VS 2032 (M Pcs) Table 35. Global Antihypertensive Drugs Sales by Application (2021-2026) & (M Pcs) Table 36. Global Antihypertensive Drugs Sales by Application (2027-2032) & (M Pcs) Table 37. Global Antihypertensive Drugs Sales Market Share by Application (2021-2026) Table 38. Global Antihypertensive Drugs Sales Market Share by Application (2027-2032) Table 39. Global Antihypertensive Drugs Revenue by Application 2021 VS 2025 VS 2032 (M Pcs) Table 40. Global Antihypertensive Drugs Revenue by Application (2021-2026) & (M Pcs) Table 41. Global Antihypertensive Drugs Revenue by Application (2027-2032) & (M Pcs) Table 42. Global Antihypertensive Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Antihypertensive Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Antihypertensive Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 45. Global Antihypertensive Drugs Sales by Region (2021-2026) & (M Pcs) Table 46. Global Antihypertensive Drugs Sales Market Share by Region (2021-2026) Table 47. Global Antihypertensive Drugs Sales Forecasted by Region (2027-2032) & (M Pcs) Table 48. Global Antihypertensive Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 50. North America Antihypertensive Drugs Sales by Country (2021-2026) & (M Pcs) Table 51. North America Antihypertensive Drugs Sales by Country (2027-2032) & (M Pcs) Table 52. Europe Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 53. Europe Antihypertensive Drugs Sales by Country (2021-2026) & (M Pcs) Table 54. Europe Antihypertensive Drugs Sales by Country (2027-2032) & (M Pcs) Table 55. Asia Pacific Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 56. Asia Pacific Antihypertensive Drugs Sales by Country (2021-2026) & (M Pcs) Table 57. Asia Pacific Antihypertensive Drugs Sales by Country (2027-2032) & (M Pcs) Table 58. South America, Middle East and Africa Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 59. South America, Middle East and Africa Antihypertensive Drugs Sales by Country (2021-2026) & (M Pcs) Table 60. South America, Middle East and Africa Antihypertensive Drugs Sales by Country (2027-2032) & (M Pcs) Table 61. Global Antihypertensive Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Antihypertensive Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Antihypertensive Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Antihypertensive Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Antihypertensive Drugs Revenue Market Share by Region (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Takeda Antihypertensive Drugs Product Portfolio Table 70. Takeda Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sanofi Antihypertensive Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Antihypertensive Drugs Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis Antihypertensive Drugs Product Portfolio Table 85. Novartis Recent Development Table 86. Merck Company Information Table 87. Merck Business Overview Table 88. Merck Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Merck Antihypertensive Drugs Product Portfolio Table 90. Merck Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pfizer Antihypertensive Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. United Therapeutics Company Information Table 97. United Therapeutics Business Overview Table 98. United Therapeutics Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. United Therapeutics Antihypertensive Drugs Product Portfolio Table 100. United Therapeutics Recent Development Table 101. Ranbaxy Laboratories Company Information Table 102. Ranbaxy Laboratories Business Overview Table 103. Ranbaxy Laboratories Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Ranbaxy Laboratories Antihypertensive Drugs Product Portfolio Table 105. Ranbaxy Laboratories Recent Development Table 106. Lupin Company Information Table 107. Lupin Business Overview Table 108. Lupin Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Lupin Antihypertensive Drugs Product Portfolio Table 110. Lupin Recent Development Table 111. Daiichi Sankyo Company Information Table 112. Daiichi Sankyo Business Overview Table 113. Daiichi Sankyo Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Daiichi Sankyo Antihypertensive Drugs Product Portfolio Table 115. Daiichi Sankyo Recent Development Table 116. Astra Zeneca Company Information Table 117. Astra Zeneca Business Overview Table 118. Astra Zeneca Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Astra Zeneca Antihypertensive Drugs Product Portfolio Table 120. Astra Zeneca Recent Development Table 121. Actelion Company Information Table 122. Actelion Business Overview Table 123. Actelion Antihypertensive Drugs Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Actelion Antihypertensive Drugs Product Portfolio Table 125. Actelion Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Antihypertensive Drugs Distributors List Table 129. Antihypertensive Drugs Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Antihypertensive Drugs Product Image Figure 2. Global Antihypertensive Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihypertensive Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihypertensive Drugs Sales (2021-2032) & (M Pcs) Figure 5. Global Antihypertensive Drugs Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Antihypertensive Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Calcium Antagonist Medicine Image Figure 9. Sympathetic Suppressant Image Figure 10. Diuretic Antihypertensive Image Figure 11. Renin-angiotensin System Inhibitor Image Figure 12. vasodilator Image Figure 13. Global Antihypertensive Drugs Sales by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 14. Global Antihypertensive Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antihypertensive Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Antihypertensive Drugs Revenue by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 17. Global Antihypertensive Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Antihypertensive Drugs Revenue Market Share by Type (2021-2032) Figure 19. Pregnant Woman Image Figure 20. General Patient Image Figure 21. The Old Image Figure 22. Global Antihypertensive Drugs Sales by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 23. Global Antihypertensive Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Antihypertensive Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Antihypertensive Drugs Revenue by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 26. Global Antihypertensive Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Antihypertensive Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 29. North America Antihypertensive Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 31. Canada Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 32. Mexico Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 33. Europe Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 34. Europe Antihypertensive Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 36. France Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 37. U.K. Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 38. Italy Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 39. Netherlands Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 40. Asia Pacific Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 41. Asia Pacific Antihypertensive Drugs Sales Market Share by Country (2021-2032) Figure 42. China Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 43. Japan Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 44. South Korea Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 45. Southeast Asia Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 46. India Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 47. Australia Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 48. South America, Middle East and Africa Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 49. South America, Middle East and Africa Antihypertensive Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 51. South Africa Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 52. Saudi Arabia Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 53. Turkey Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 54. Argentina Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 55. UAE Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 56. Egypt Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 57. Chile Antihypertensive Drugs Sales and Growth Rate (2021-2032) & (M Pcs) Figure 58. Global Antihypertensive Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Antihypertensive Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Antihypertensive Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Antihypertensive Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Antihypertensive Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Antihypertensive Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Antihypertensive Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Antihypertensive Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Antagonist Medicine
  • Sympathetic Suppressant
  • Diuretic Antihypertensive
  • Renin-angiotensin System Inhibitor
  • vasodilator
Applications
  • Pregnant Woman
  • General Patient
  • The Old
Companies covered
  • Takeda
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Pfizer
  • United Therapeutics
  • Ranbaxy Laboratories
  • Lupin
  • Daiichi Sankyo
  • Astra Zeneca
  • Actelion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antihypertensive Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antihypertensive Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antihypertensive Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antihypertensive Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antihypertensive Drugs Market Dynamics
  1. 2.1 Antihypertensive Drugs Industry Trends
  2. 2.2 Antihypertensive Drugs Industry Drivers
  3. 2.3 Antihypertensive Drugs Industry Opportunities and Challenges
  4. 2.4 Antihypertensive Drugs Industry Restraints
3 Antihypertensive Drugs Market by Manufacturers
  1. 3.1 Global Antihypertensive Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antihypertensive Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antihypertensive Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antihypertensive Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antihypertensive Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antihypertensive Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Antihypertensive Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antihypertensive Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antihypertensive Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antihypertensive Drugs Tier 1, Tier 2, and Tier 3
4 Antihypertensive Drugs Market by Type
  1. 4.1 Antihypertensive Drugs Type Introduction
  2. 4.1.1 Calcium Antagonist Medicine
  3. 4.1.2 Sympathetic Suppressant
  4. 4.1.3 Diuretic Antihypertensive
  5. 4.1.4 Renin-angiotensin System Inhibitor
  6. 4.1.5 vasodilator
  7. 4.2 Global Antihypertensive Drugs Sales by Type
  8. 4.2.1 Global Antihypertensive Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Antihypertensive Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Antihypertensive Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Antihypertensive Drugs Revenue by Type
  12. 4.3.1 Global Antihypertensive Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Antihypertensive Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Antihypertensive Drugs Revenue Market Share by Type (2021-2032)
5 Antihypertensive Drugs Market by Application
  1. 5.1 Antihypertensive Drugs Application Introduction
  2. 5.1.1 Pregnant Woman
  3. 5.1.2 General Patient
  4. 5.1.3 The Old
  5. 5.2 Global Antihypertensive Drugs Sales by Application
  6. 5.2.1 Global Antihypertensive Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antihypertensive Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Antihypertensive Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antihypertensive Drugs Revenue by Application
  10. 5.3.1 Global Antihypertensive Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antihypertensive Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Antihypertensive Drugs Revenue Market Share by Application (2021-2032)
6 Global Antihypertensive Drugs Sales by Region
  1. 6.1 Global Antihypertensive Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antihypertensive Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Antihypertensive Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Antihypertensive Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antihypertensive Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antihypertensive Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antihypertensive Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antihypertensive Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antihypertensive Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antihypertensive Drugs Revenue by Region
  1. 7.1 Global Antihypertensive Drugs Revenue by Region
  2. 7.1.1 Global Antihypertensive Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antihypertensive Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Antihypertensive Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Antihypertensive Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antihypertensive Drugs Revenue (2021-2032)
  8. 7.2.2 North America Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antihypertensive Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antihypertensive Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antihypertensive Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antihypertensive Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Antihypertensive Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Antihypertensive Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Antihypertensive Drugs Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Antihypertensive Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Antihypertensive Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Antihypertensive Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 United Therapeutics
  38. 8.7.1 United Therapeutics Company Information
  39. 8.7.2 United Therapeutics Business Overview
  40. 8.7.3 United Therapeutics Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 United Therapeutics Antihypertensive Drugs Product Portfolio
  42. 8.7.5 United Therapeutics Recent Developments
  43. 8.8 Ranbaxy Laboratories
  44. 8.8.1 Ranbaxy Laboratories Company Information
  45. 8.8.2 Ranbaxy Laboratories Business Overview
  46. 8.8.3 Ranbaxy Laboratories Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ranbaxy Laboratories Antihypertensive Drugs Product Portfolio
  48. 8.8.5 Ranbaxy Laboratories Recent Developments
  49. 8.9 Lupin
  50. 8.9.1 Lupin Company Information
  51. 8.9.2 Lupin Business Overview
  52. 8.9.3 Lupin Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lupin Antihypertensive Drugs Product Portfolio
  54. 8.9.5 Lupin Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Antihypertensive Drugs Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca Antihypertensive Drugs Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
  67. 8.12 Actelion
  68. 8.12.1 Actelion Company Information
  69. 8.12.2 Actelion Business Overview
  70. 8.12.3 Actelion Antihypertensive Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Actelion Antihypertensive Drugs Product Portfolio
  72. 8.12.5 Actelion Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antihypertensive Drugs Value Chain Analysis
  2. 9.1.1 Antihypertensive Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antihypertensive Drugs Production Mode & Process
  6. 9.2 Antihypertensive Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antihypertensive Drugs Distributors
  9. 9.2.3 Antihypertensive Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst